Newsroom
Sorted by: Latest
-
Die Baszucki Group finanziert eine klinische Studie der Universität Oxford zur ketogenen Therapie bei frühzeitiger Psychose
SAN MATEO, Kalifornien--(BUSINESS WIRE)--Die Baszucki Group gab heute bekannt, dass sie eine Förderung in Höhe von 1,17 Millionen Pfund für eine randomisierte kontrollierte Studie an der Universität Oxford bereitstellt, in der die Durchführbarkeit, Sicherheit und Wirksamkeit einer ketogenen Diät bei Patienten mit einem hohen klinischen Psychoserisiko (CHR-P) untersucht werden soll. Die Forscher werden untersuchen, inwieweit diese Ernährungstherapie die geistige und körperliche Gesundheit der Pa...
-
Keller Williams Announces CEO Summit Speakers for Mega Camp 2026
AUSTIN, Texas--(BUSINESS WIRE)--Amy Porterfield, John Lee, Dan Buettner, Shawn Johnson East, and Andrew East to headline KW’s CEO Summit....
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat)...
-
全球巨星Ahn Hyo-seop與Khalid今日透過FANDOM推出跨界全新單曲《Something Special》
洛杉磯和韓國首爾--(BUSINESS WIRE)--(美國商業資訊)-- 今天,國際巨星Ahn Hyo-seop與多白金唱片歌手Khalid備受期待的跨界合作單曲《Something Special》正式發行,目前已透過FANDOM登陸各大主流串流媒體平台。如欲串流播放單曲,請點選此處。Musicow還將於6月發表官方MV,屆時將展現Ahn Hyo-seop與Khalid之間獨特的化學反應,同時在螢幕上生動呈現這場跨文化合作的魅力。 Ahn Hyo-seop因在Netflix爆款卡通片《K-Pop獵魔女團》(KPop Demon Hunters)中飾演惡魔男團「Saja Boys」的隊長「Jinu」一角而享譽全球。此次,他與曾獲葛萊美獎提名的歌手Khalid強強聯手,帶來了一首完美融合韓國流行音樂(K-pop)與美國節奏藍調(R&B)風格的跨流派作品。這兩種音樂流派正是當今重塑全球音樂文化最具影響力的力量。 《Something Special》由曾為傳奇K-pop組合Wonder Girls打造經典歌曲《Nobody》的Woo “RAINSTONE” Rhee操刀製作,並由...
-
アン・ヒョソプとカリード、クロスマーケット・シングル「Something Special」をFANDOMより本日リリース
米国ロサンゼルス/韓国ソウル--(BUSINESS WIRE)--(ビジネスワイヤ) -- 待望のクロスマーケット・コラボレーション楽曲「Something Special」が正式にリリースされました。国際的スターであるアン・ヒョソプとマルチプラチナ・アーティストのカリードによる本作は、FANDOMより配信され、主要なストリーミングプラットフォームで視聴可能です。(ストリーミングはこちらから)なお、Musicowは6月に公式ミュージックビデオを公開予定で、アン・ヒョソプとカリードの独自のケミストリーを際立たせるとともに、本楽曲の異文化を横断するコラボレーションを映像として表現します。 アン・ヒョソプは、Netflixのアニメーション作品「K-Pop Demon Hunters」に登場するデーモン・ボーイバンド「Saja Boys」のリーダー「ジヌ」役で世界的に知られており、今回、グラミー賞ノミネート歴を持つカリードとのコラボレーションが実現しました。本作は、現代のグローバル音楽カルチャーを牽引する2大潮流であるK-POPと米国R&Bの融合したジャンル横断的な作品となっています...